Tonix Pharmaceuticals Holding

Company snapshot

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure s

• 2 approved product(s) across US/EU regulatory metadata.
• 30 active pipeline program(s) linked via ClinicalTrials.gov.
• 86 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Tonix Pharmaceuticals Holding. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Tonix Pharmaceuticals Holding.

1. Jun 8, 2026 Clinical update

   2017-004466-98 — Phase 1

2. Jun 8, 2026 Clinical update

   Intranasal Oxytocin (IN-OXT) — Phase 1

3. Jun 8, 2026 Clinical update

   Cyclobenzaprine HCl — Phase 2

4. Jun 5, 2026 Clinical update

   Treatment A — Phase 1

5. Jun 5, 2026 Clinical update

   Treatment A — Phase 1

View all clinical trial activity →

• What is Tonix Pharmaceuticals Holding?

  Tonix Pharmaceuticals is a pharma organization headquartered in Berkeley Heights, USA. It trades on NYSE under ticker TNXP. Primary therapeutic focus areas include Fibromyalgia, Primary Fibromyalgia, PTSD, Acute Stress Reaction, Pain, Face. NovaPharmaNews links 30 clinical progra

• Is Tonix Pharmaceuticals Holding publicly traded?

  Yes. Tonix Pharmaceuticals Holding is listed with ticker TNXP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Tonix Pharmaceuticals Holding develop or market?

  We link 10 drug profile(s) where Tonix Pharmaceuticals Holding is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tonix-pharmaceuticals-holding#company-drugs.

• What are the latest developments for Tonix Pharmaceuticals Holding?

  In the last 12 months our linked public records show 30 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Tonix Pharmaceuticals Holding focus on?

  Tonix Pharmaceuticals Holding focuses on Fibromyalgia, Primary Fibromyalgia, PTSD based on our analysis of their pipeline programs and drug development activities.